Contraception

Low-dose mifepristone 200 mg and vaginal misoprostol for abortion - women's preferences and acceptability of treatment
pp. 1-6(6)
Authors: Schaff E.A.; Eisinger S.H.; Stadalius L.S.; Franks P.; Gore B.Z.; Poppema S.

Comparing abortion induced with methotrexate and misoprostol to methotrexate alone - efficacy and early medical sequelae
pp. 7-10(4)
Author: Wiebe E.R.

A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion - a randomized trial comparing misoprostol 3 days and 7 days following methotrexate
pp. 11-16(6)
Authors: Creinin M.D.; Carbonell J.L.L.; Schwartz J.L.; Varela L.; Tanda R.

Effect of oral contraceptives containing 20 and 35 g ethinyl estradiol on urinary prostacyclin and thromboxane metabolite levels in smokers and nonsmokers - should epidemiologic associations drive clinical decision-making
pp. 17-23(7)
Authors: Stanczyk F.Z.; Ploszaj S.; Gentzschein E.; Qian D.; Mishell D.R.

Long-term depot-medroxyprogesterone acetate and bone mineral density - a randomised, double-blind, one year trial of conjugated estrogen or medroxyprogesterone acetate
pp. 25-29(5)
Authors: Tang O.S.; Tang G.; Yip P.; Li B.; Fan S.

Study of the effects of the implantable contraceptive Norplant(R) on lipid and lipoprotein metabolism1
pp. 31-45(15)

Optical testing of condoms - Testing for holes-Determination of bursting volume and pressure: ISO 4074-6
pp. 47-57(11)
Authors: Smith S.R.; Lowrance J.L.; Tessarotto L.A.B.

Clinical acceptability of an ethylene-vinyl-acetate nonmedicated vaginal ring
pp. 59-62(4)
Authors: Roumen F.J.M.E.; Dieben T.O.M.

Uterine histopathologic changes after Cu-fix intrauterine device insertion
pp. 63-65(3)
Authors: Reinprayoon D.; Taneepanichskul S.; Niruthisard S.; Suwajanakon S.

Reactive oxygen intermediates and reactive nitrogen intermediates in copper intrauterine device users - a bacteriological study of the endometrial cavity
pp. 67-70(4)
Authors: Anjalika; Gupta I.; Gupta S.K.; Ganguly N.K.